| Website | cmcapital.com |
| Phone | +61 7 3838 2800 |
| Employees | |
| Description | capital fund |
CM Capital invests in companies that offer differentiated products with high barriers to entry and substantial market opportunities. We also value talented management teams who have the skill, drive and enthusiasm to take their companies to a market leadership position.
| Company | Date | Round | Size | Participants |
| Pathway Therapeutics | 5/11 | Series A | $7.5M | 2 |
| Mantara | 5/11 | Unattributed | $7M | 3 |
| Datacastle | 2/11 | Unattributed | $2M | 1 |
| ThreatMetrix | 10/10 | Series C | $12.1M | 4 |
| Pathway Therapeutics | 8/10 | Series A | $4.5M | 3 |
| Datacastle | 11/09 | Unattributed | $3M | 1 |
| Dilithium Networks | 10/09 | Unattributed | $10.9M | 6 |
| Pathway Therapeutics | 10/09 | Series A | $2.4M | 2 |
| ThreatMetrix | 10/09 | Series B | $6.1M | 2 |
| Mantara | 5/09 | Series C | $7.6M | 4 |
| Piedmont Pharmaceuticals | 4/09 | Unattributed | $5M | 1 |
| Datacastle | 11/08 | Series A | $5.3M | 1 |
| Xumii | 9/08 | Unattributed | $5.5M | 2 |
| Mantara | 7/08 | Unattributed | $5.8M | 4 |
| Pathway Therapeutics | 6/08 | Series A | $9.6M | 2 |
| AdGent Digital | 3/08 | Series A | $5.3M | 1 |
| Xumii | 11/07 | Unattributed | $4.3M | 2 |
| Mantara | 9/07 | Series B | $12.8M | 4 |
| Dilithium Networks | 11/06 | Series D | $16.8M | 5 |
| bCODE | 10/05 | Series A | $3.79M | 2 |
| Dilithium Networks | 3/05 | Series C | $18M | 6 |
| Dilithium Networks | 4/03 | Series B | $10M | 5 |